---
figid: PMC5693226__nihms918533f1
figtitle: Rationale for mTOR inhibitor + NOTCH inhibitor combination
organisms:
- NA
pmcid: PMC5693226
filename: nihms918533f1.jpg
figlink: /pmc/articles/PMC5693226/figure/F1/
number: F1
caption: 'Rationale for mTOR inhibitor + NOTCH inhibitor combination. The PI3K/AKT/mTOR
  signaling pathway is aberrantly activated in a variety of cancers. Notch signaling
  has been shown to maintain cell proliferation, growth, and metabolism in part by
  driving PI3K pathway signaling. The combination of mTOR inhibitor ridaforolimus
  and Notch inhibitor MK-0752 may lead to complementary blockade of the PI3K pathway.Abbreviations:
  AKT, protein kinase-B; DLL4, Delta-like ligand 4; HES1, Hairy/enhancer of split
  1; HIF, hypoxia-inducible factor; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
  3-kinase; PTEN, phosphatase and tensin homolog; rida, ridaforolimus; RTK, receptor
  tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.'
papertitle: Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients
  with advanced solid tumors.
reftext: S.A. Piha-Paul, et al. Eur J Cancer. ;51(14):1865-1873.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.950262
figid_alias: PMC5693226__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5693226__F1
ndex: 5e619077-def4-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5693226__nihms918533f1.html
  '@type': Dataset
  description: 'Rationale for mTOR inhibitor + NOTCH inhibitor combination. The PI3K/AKT/mTOR
    signaling pathway is aberrantly activated in a variety of cancers. Notch signaling
    has been shown to maintain cell proliferation, growth, and metabolism in part
    by driving PI3K pathway signaling. The combination of mTOR inhibitor ridaforolimus
    and Notch inhibitor MK-0752 may lead to complementary blockade of the PI3K pathway.Abbreviations:
    AKT, protein kinase-B; DLL4, Delta-like ligand 4; HES1, Hairy/enhancer of split
    1; HIF, hypoxia-inducible factor; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
    3-kinase; PTEN, phosphatase and tensin homolog; rida, ridaforolimus; RTK, receptor
    tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - DLL4
  - HES1
  - GATD3
  - PTEN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KDR
  - FLT1
  - FLT4
  - AKT1
  - AKT2
  - AKT3
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - MTOR
  - RIDA
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - MK-0752
  - Cancer
---
